Kind and distribution of cutaneous sensation loss in hereditary transthyretin amyloidosis with polyneuropathy

被引:7
|
作者
Pinto, Marcus V. [1 ,2 ]
Dyck, P. James B. [1 ]
Gove, Linde E. [1 ]
McCauley, Bryan M. [1 ]
Ackermann, Elizabeth J. [3 ]
Hughes, Steven G. [3 ]
Waddington-Cruz, Marcia [2 ]
Dyck, Peter J. [1 ]
机构
[1] Mayo Clin, Dept Neurol, 200 First St SW, Rochester, MN 55905 USA
[2] Univ Fed Rio de Janeiro, Dept Neurol, Natl Amyloidosis Referral Ctr CEPARM, Rio De Janeiro, Brazil
[3] IONIS Pharmaceut Inc, 2855 Gazelle Court, Carlsbad, CA 92010 USA
关键词
Hereditary transthyretin amyloidosis; Peripheral neuropathy; Familial amyloid polyneuropathy; Sensation loss; Smart somatotopic quantitative sensory testing; NERVE; JAPAN;
D O I
10.1016/j.jns.2018.08.031
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: Report on the kind and distribution of somatotopic sensation loss and its utility in assessing severity of sensation loss in study of a large international cohort of patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN). Methods: Smart Somatotopic Quantitative Sensation Testing (S ST QSTing) using Computer Assisted Sensation Evaluator IVc (CASE IVc) was used to assess the somatotopic distribution of touch pressure (TP) and heat pain (HP) sensation loss twice of untreated hATTR-PN patients in the Ionis NEURO-TTR trial (www.clinicaltrials.gov, NCT01737398). Results: Of the studied cohort of 169 patients, 163 (97%) had sensation loss, both TP and HP in 121/169 (75%), TP only in 39/169 (23%), and HP only in 3/169 (2%). Sensation loss typically affected both lower (152/169-90%) and upper limb (135/169-82%), and overall TP sensation loss was greater than HP loss, except for early-onset Val30Met patients in which HP exceeded TP loss. Conclusion: Using S ST QSTing, a highly quantitated, standardized, referenced, and automated QSTing approach of the body's surface distribution of sensation loss we have shown that: 1) reliable and useful measurement of the body surface distribution of sensation loss is possible; 2) this measure is abnormal in most patients with hATTR-PN and is an indication of polyneuropathy severity; and 3) cutaneous sensation loss involves both large and small sensory fibers in this disease but slightly more small fibers in early onset Val30Met patients.
引用
收藏
页码:78 / 83
页数:6
相关论文
共 50 条
  • [1] Hereditary Transthyretin Amyloidosis Polyneuropathy
    Qarni, Taha
    Moshe-Lilie, Orly
    Kaku, Michelle C.
    Karam, Chafic
    SEMINARS IN NEUROLOGY, 2025, 45 (01) : 75 - 87
  • [2] Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy
    Coelho, Teresa
    Marques, Wilson, Jr.
    Dasgupta, Noel R.
    Chao, Chi-Chao
    Parman, Yesim
    Franca, Marcondes Cavalcante, Jr.
    Guo, Yuh-Cherng
    Wixner, Jonas
    Ro, Long-Sun
    Calandra, Cristian R.
    Kowacs, Pedro A.
    Berk, John L.
    Obici, Laura
    Barroso, Fabio A.
    Weiler, Markus
    Conceicao, Isabel
    Jung, Shiangtung W.
    Buchele, Gustavo
    Brambatti, Michela
    Chen, Jersey
    Hughes, Steven G.
    Schneider, Eugene
    Viney, Nicholas J.
    Masri, Ahmad
    Gertz, Morie R.
    Ando, Yukio
    Gillmore, Julian D.
    Khella, Sami
    Dyck, P. James B.
    Cruz, Marcia Waddington
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 330 (15): : 1448 - 1458
  • [3] Hereditary Transthyretin Amyloidosis with Polyneuropathy: Monitoring and Management
    Velez-Santamaria, Valentina
    Nedkova-Hristova, Velina
    Morales de la Prida, Moises
    Casasnovas, Carlos
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2022, 15 : 8677 - 8684
  • [4] Canadian Guidelines for Hereditary Transthyretin Amyloidosis Polyneuropathy Management
    Alcantara, Monica
    Mezei, Michelle M.
    Baker, Steven K.
    Breiner, Ari
    Dhawan, Priya
    Fiander, Amanda
    Fine, Nowell M.
    Hahn, Christopher
    Katzberg, Hans D.
    Khayambashi, Shahin
    Massie, Rami
    Matte, Genevieve
    Putko, Brendan
    Siddiqi, Zaeem
    Delgado, Diego
    Bril, Vera
    CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 2022, 49 (01) : 7 - 18
  • [5] Societal costs and burden of hereditary transthyretin amyloidosis polyneuropathy
    Ines, Monica
    Coelho, Teresa
    Conceicao, Isabel
    Landeiro, Filipa
    de Carvalho, Mamede
    Costa, Joao
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2020, 27 (02): : 89 - 96
  • [6] QUANTITATIVE SENSATION AND AUTONOMIC TEST ABNORMALITIES IN TRANSTHYRETIN AMYLOIDOSIS POLYNEUROPATHY
    Kim, Dong Hwee
    Zeldenrust, Steven R.
    Low, Phillip A.
    Dyck, Peter J.
    MUSCLE & NERVE, 2009, 40 (03) : 363 - 370
  • [7] Magnetization transfer ratio quantifies polyneuropathy in hereditary transthyretin amyloidosis
    Kollmer, Jennifer
    Hegenbart, Ute
    Kimmich, Christoph
    Hund, Ernst
    Purrucker, Jan C.
    Hayes, John M.
    Lentz, Stephen, I
    Sam, Georges
    Jende, Johann M. E.
    Schoenland, Stefan O.
    Bendszus, Martin
    Heiland, Sabine
    Weiler, Markus
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2020, 7 (05): : 799 - 807
  • [8] Vutrisiran: A Review in Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis
    Nie, Tina
    Heo, Young-A
    Shirley, Matt
    DRUGS, 2023, 83 (15) : 1425 - 1432
  • [9] Corneal Nerve Fiber Length In Hereditary Transthyretin Amyloidosis Polyneuropathy
    Alcantara, Monica
    Mannan, Shabber
    Perkins, Bruce
    Bril, Vera
    NEUROLOGY, 2020, 94 (15)
  • [10] Inotersen to Treat Polyneuropathy Associated with Hereditary Transthyretin (hATTR) Amyloidosis
    Robinson, Christopher
    Pham, Cynthia
    Zamarripa, Alec M.
    Dugay, Chase S.
    Lee, Christopher A.
    Berger, Amnon A.
    Landman, Avi
    Cornett, Elyse M.
    Kassem, Hisham
    Kaye, Alan D.
    Urits, Ivan
    Viswanath, Omar
    Ganti, Latha
    HEALTH PSYCHOLOGY RESEARCH, 2022, 10 (05):